Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

R 125489

Known as: R-125489, R125489 
 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Zanamivir
analogs & derivatives

Narrower (2)

laninamivirlaninamivir octanoate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Two neuraminidase inhibitors, oseltamivir and zanamivir, are important drug treatments for influenza. Oseltamivir-resistant… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the treatment… Expand
  • table 1
Is this relevant?
2010
2010
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
BACKGROUND Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use for the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
CS-8958, a prodrug of laninamivir (R-125489), is currently under development as an inhaled anti-influenza drug. In this study… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2010
Review
2010
Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
Oseltamivir and zanamivir are currently licensed worldwide for influenza treatment and chemoprophylaxis. Both drugs require twice… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment… Expand
Is this relevant?
2009
2009
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
CS-8958 is a prodrug of the pharmacologically active form R-125489, a selective neuraminidase inhibitor, and has long-acting anti… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
R-118958, a unique anti-influenza agent showing high efficacy for both prophylaxis and treatment after a single administration: from the in vitro stage to phase I study
Abstract R-118958 is a prodrug of R-125489, which is a neuraminidase inhibitor that potently inhibits influenza A and B viral… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE